Cargando…

Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names

By combining and cross-checking data from the World Health Organization’s lists of international nonproprietary names with three other databases, we assembled a dataset of amino acid sequences of 819 antibody-related therapeutics. This enabled the systematic tabulation of 57 different molecular form...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilkinson, Ian, Hale, Geoff
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481088/ https://www.ncbi.nlm.nih.gov/pubmed/36109838 http://dx.doi.org/10.1080/19420862.2022.2123299

Ejemplares similares

The INNs and outs of antibody nonproprietary names
por: Jones, Tim D., et al.
Publicado: (2015)

International nonproprietary names for monoclonal antibodies: an evolving nomenclature system
por: Guimaraes Koch, Sofia S., et al.
Publicado: (2022)

Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more
por: Parren, Paul W. H. I., et al.
Publicado: (2017)

Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names
por: Bryan, Rachel, et al.
Publicado: (2015)

International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety
por: Robertson, James S., et al.
Publicado: (2022)

The Impact of International Nonproprietary Names Integration on Prescribing Reimbursement Medicines for Arterial Hypertension and Analysis of Medication Errors in Latvia
por: Gavrilova, Anna, et al.
Publicado: (2022)

International nonproprietary names (INN) for pharmaceuticals substances : lists 1-73 of proposed INN and lists 1-35 of recomended INN cumulative list No. 9 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques : listes 1-73 de DCI proposées et listes 1-35 de DCI recommandées liste récapitulative No. 9
Publicado: (1996)

International nonproprietary names (INN) for pharmaceutical substances, : lists 1-65 of proposed INN and lists 1-31 of recommended INN : cumulative list no. 8 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques, listes 1-65 de DCI proposées et listes 1-31 de DCI recommandées : liste récapitulative no. 8.
Publicado: (1992)

International nonproprietary names (INN) for pharmaceutical substances : lists 1-65 of proposed INN and lists 1-31 of recommended INN : cumulative list no. 8 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques : listes 1-65 de DCI proposées et listes 1-31 de DCI recommandées : liste récapitulative no. 8.
Publicado: (1992)

The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough
por: Loizides, Ursula, et al.
Publicado: (2021)

International nonproprietary names (INN) for pharmaceutical substances, 1988 : lists 1-58 of proposed INN and lists 1-27 of recommended INN : cumulative list no. 7 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques, 1988 : listes 1-58 de DCI proposées et listes 1-27 de DCI recommandées : liste récapitulative no. 7.
Publicado: (1988)

International nonproprietary names (INN) for pharmaceutical substances, 1982 : lists 1-47 of proposed INN and lists 1-21 of recommended INN : cumulative list no. 6 = Dénominations communes internationales (DCI) pour les substances pharmaceutiques, 1982 : listes 1-47 de DCI proposées et listes 1-21 de DCI recommandées : liste récapitulative no. 6.
Publicado: (1982)

Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names
por: Chao, Jingdong, et al.
Publicado: (2015)

Fc-engineered antibodies with immune effector functions completely abolished
por: Wilkinson, Ian, et al.
Publicado: (2021)

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
por: Correale, Jorge, et al.
Publicado: (2016)

Synthesis of the 8,19‐Epoxysteroid Eurysterol A
por: Taspinar, Ömer, et al.
Publicado: (2020)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
por: Liu, Liming
Publicado: (2017)

819. Experience with Isavuconazole Use for Treatment of Invasive Fungal Infections
por: Gow-Lee, Vanessa, et al.
Publicado: (2023)

Aerosolized BC-819 Inhibits Primary but Not Secondary Lung Cancer Growth
por: Hasenpusch, Günther, et al.
Publicado: (2011)

The IL-10 -819T polymorphism is associated with increased susceptibility to severe sepsis
por: Wood, KA, et al.
Publicado: (2003)

Interleukin-10-819 promoter polymorphism in association with gastric cancer risk
por: Xue, Huiping, et al.
Publicado: (2012)

The association of interleukin-10 -1082, -819, -592 polymorphisms and tuberculosis risk
por: Liu, Qianqian, et al.
Publicado: (2015)

HUSH-mediated HIV silencing is independent of TASOR phosphorylation on threonine 819
por: Vauthier, Virginie, et al.
Publicado: (2022)

Gaps between actual initial treatment of anaphylaxis in China and international guidelines: A review and analysis of 819 reported cases
por: Jiang, Chunyan, et al.
Publicado: (2019)

Therapeutic Fc fusion protein misfolding: A three-phasic cultivation experimental design
por: Ghorbani Aghdam, Atefeh, et al.
Publicado: (2019)

Fc glycans of therapeutic antibodies as critical quality attributes
por: Reusch, Dietmar, et al.
Publicado: (2015)

Editorial: Antibody Fc Engineering: Towards Better Therapeutics
por: Lei, Cheng, et al.
Publicado: (2018)

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
por: Gogesch, Patricia, et al.
Publicado: (2021)

NMDA-receptor-Fc-fusion constructs neutralize anti-NMDA receptor antibodies
por: Steinke, Stephan, et al.
Publicado: (2023)

Measurement of neutron-proton charge exchange scattering at 8,19 and 24 GeV/c
por: Ellis, Jonathan Richard, et al.
Publicado: (1971)

A satellite DNA array barcodes chromosome 7 and regulates totipotency via ZFP819
por: Fernandes, Liane P., et al.
Publicado: (2022)

Removing chaos from confusion: assigning names to common human and animal pathogens in Neocosmospora
por: Sandoval-Denis, M., et al.
Publicado: (2018)

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

Boosting therapeutic potency of antibodies by taming Fc domain functions
por: Kang, Tae Hyun, et al.
Publicado: (2019)

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
por: Abdeldaim, Dalia T., et al.
Publicado: (2023)

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
por: Ha, Ji-Hee, et al.
Publicado: (2016)

Computational Design of a DNA- and Fc-Binding Fusion Protein
por: Winkler, Jonas, et al.
Publicado: (2011)

Association between interleukin-10-819T/C polymorphism and risk of ischemic stroke: A meta-analysis
por: Zuo, Shuang, et al.
Publicado: (2020)

Automated group assignment in large phylogenetic trees using GRUNT: GRouping, Ungrouping, Naming Tool
por: Dalevi, Daniel, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_i5d4nio3nvqsli7qjd37i8ki59